Time to buy pharma? 3 stocks Forum Parekh is betting on

economictimes.indiatimes.com:

Foram Parekh, Associate V-P,Sharekhan By BNP Paribas, says from the domestic pharma side, he likes Torrent and from the US side, Lupin and Sun Pharma. Zydus Life is also there. They like Sun because despite all the plant problems that this company is facing, its US specialty drug is doing good and it will continue to do good. Even it has new product launches coming up next month in the specialty side.

Zydus got the US FDA approval for an Edarbi drug. The stock is sitting at a one-month high level. The updates that we have got concerning the Q1 domestic as well as the import data suggest that this quarter is going to be strong. What are your expectations concerning Zydus Life and the stock movement going forward?
Foram Parekh: We like Zydus Life and we also believe that this quarter is going to be healthy for Zydus because its US business is doing good. Also, it has launched Mirabegron in the US market which is a very big product and almost has a market size of $1 billion. Zydus has launched it in two strengths – 25 and 50 mg and it is the sole player to launch in 50 mg.

Unlock Leadership Excellence with a Range of CXO Courses

So, this will reap the benefits in the US market and will lead to an increase in the margins. Also, it has many specialty products and novel products which are in the advanced stage of its clinical trials, which